Skip Navigation

European Heart Journal 1993 14(Supplement G):48-51; doi:10.1093/eurheartj/14.suppl_G.48
Copyright © 1993 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1993 The European Society of Cardiology

Free radicals, reperfusion and myocardial infarction therapy: European Myocardial Infarction Project — free radicals pilot study

Emip-Fr Pilor Study Group*

Correspondence: J. P. Boissel. EMIP-FR Coordinating Centre, 162 avenue Lacassagne, Boite Postale 3041, 69394 Lyon Cedex 03, France

Reperfusion injury due to overproduction of free radicals may reduce the efficacy of thrombolytic therapy. Trimetazidine is an agent which could prevent or limit the deleterious effects of free radicals on the myocardium and could, therefore improve the prognosis for patients with acute myocardial infarction (MI) receiving thrombolytic therapy.

In this pilot study, 136 patients with suspected acute MI were randomized to receive either 40 mg trimetazidine as are intravenous (i.v.) bolus followed by an infusion of trimetazidine at 60 mg. 24 h–1 for 48 h (n = 69) or matching placebo (n = 67). Stratification was based on the use ("7" stratum; n = 69) or not (‘NT’ stratum; n = 67) of a thrombolytic. The mean age of patients was 64.2 years (± 12.7), and the final diagnosis at discharge was confirmed MI in 92% of patients. No statistically significant difference was observed for the occurrence of major or minor adverse events. Eight patients diea before discharge; three in the trimetazidine group and five in the placebo group.

The observed compliance was good and the low rate of adverse events suggests that the study treatment can be considered safe in patients with suspected acute MI, either receiving thrombolytic treatment or not. The study is feasible and no major practical problem can be expected from this simple protocol. We started recruitment of patients for the large-scale mortality and morbidity trial in October 1992.

Key Words: Randomized clinical trials • free radicals • acute myocardial infarction

* See appendix for members.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.